ArticleJACC. Basic to translational science2024
Efficacy and Safety of Dual Paclitaxel and Sirolimus Nanoparticle-Coated Balloon.
Article in JACC. Basic to translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06373601 (Selution Sirolimus Coated Balloon), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Selution Sirolimus Coated Balloon (MedAlliance) Versus SeQuent Please Neo Paclitaxel Coated Balloon (Bbraun) for the Treatment of de Novo Coronary Artery Lesions in Medium-small Size Vessels.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Drug-Coated Balloons Versus Other Percutaneous Coronary Intervention Strategies in De Novo Coronary Artery Disease: A Systematic Review, Meta-Analysis With Trial Sequential Analysis.Cardiovascular therapeutics · 2026Pooled it
- Recurrent In-Stent Restenosis Treated With a Novel Technique: The Double-DCB Technique.JACC. Case reports · 2026Article
- Angiographic and functional assessment after paclitaxel or sirolimus drug-coated balloons for de novo coronary artery disease in small vessels: PICCOLETO VI study.AsiaIntervention · 2026Article
- Artificial Intelligence in Drug-Coated Cardiovascular Devices: A Narrative Review.Reviews in cardiovascular medicine · 2025Review
- Treatment Options in Isolated Atherosclerotic Popliteal Artery Disease.Journal of cardiovascular development and disease · 2025Review
- Drug Loss at Arterial Bends Can Dominate Off-Target Drug Delivery by Paclitaxel-Coated Balloons.Pharmaceutics · 2025Article
- Peripheral artery disease and local drug delivery: a review of disease pathology and drug delivery systems for therapy below the knee.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- New Drug-Coated Balloons on the Horizon: The Quest for a Good Balance Between Safety and Efficacy.JACC. Basic to translational science · 2024Article
- Paclitaxel- and Sirolimus-Coated Drug-Coated Balloons versus Drug-Eluting Stents in Acute Myocardial Infarction: A Comprehensive Systematic Review and Meta-Analysis.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated a novel dual active pharmaceutical ingredient (API) drug-coated balloon (DCB), which consists of a coating of nanoparticles encapsulating low-dose paclitaxel (PTX) in combination with sirolimus in a synergistic ratio. Compared to the PTX DCB, the dual API DCB demonstrated similar inhibition of cell proliferation in vitro but at a significantly lower total drug dose (over 13 times lower than sirolimus nanoparticles). Animal experiments demonstrated that the dual API DCB is more effective in inhibiting intimal cell proliferation with insignificant downstream embolic effects and myocardial damage compared to the PTX DCB. These findings indicate that dual API DCBs have a high potential to demonstrate improved clinical outcomes and a greater safety profile than the PTX DCBs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.